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0024-3205 © 2014 Elsevier Inc. Open access under CC Ba b s t r a c ta r t i c l e i n f oAvailable online 28 September 2014 Twenty-ﬁve years ago, a groundbreaking paper from Tsukuba University in Japanwas published, identifying the se-
quence of the endothelin gene and peptide (Nature 332, 411–415, 1988). This work opened the way for the
discovery of the endothelin receptors and the development of orally active endothelin receptor antagonists
(ERAs). Today, ERAs are part of medical therapy of patients around the world for the treatment of pulmonary
arterial hypertension. Since the discovery of endothelin, about 1000 papers per year have been published, with
more than 27,000 articles available today. Many important and break-through ﬁndings presented in the endothelin
conferences have been published in the conferences' proceedings. Endothelin XIII is the proceedings of the Thir-
teenth International Conference on Endothelin, held at Tokyo Campus of Tsukuba University, Japan, in September
2013. At the conference, the 25th anniversary of endothelin's discovery was celebrated and articles produced
from data presented at the conference are compiled in this Special Issue of Life Sciences. Endothelin XIII includes
more than ﬁfty articles, including review articles by experts in the ﬁeld and numerous original research articles.
As the Editors of this special issue, we are proud to present Endothelin XIII and wish the ﬁeld continued growth
for the beneﬁt of patients and for the advancement of biomedical science.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.Over the past 25 years, the International Conferences on Endothelin
have contributed to the development of endothelin research by providing
the place to share the most recent and up-to-date information on
endothelin (Emoto et al., 2014b). Also, the conferences have developed
into meetings where young researchers and senior scientists from the
most diverse disciplines and from all regions around the world come
together to meet and to discuss and share their recent ﬁndings (Emoto
et al., 2014b). The First International Conference on Endothelin was
launched as the “First William Harvey Workshop on Endothelin” in
December of 1988 and chaired by Sir John Vane, Ph.D., FRS, in
London, U.K. (Vane et al., 1989), less than nine months after thearmacy, Kobe Pharmaceutical
partment of Internal Medicine,
-0017 Japan. Tel.: +81 78 382
Y-NC-ND license.publication of the molecular structure of the endothelin gene and pep-
tide (Yanagisawa et al., 1988). Since then, the International Conferences
on Endothelin have been held every other year and many of the scientif-
ically important advances of the ﬁeld were published in the conference
proceedings (Barton, 2012; Battistini et al., 2000; d'Orleans-Juste,
2010a, b; d'Orleans-Juste et al., 2008a, b; Emoto, 2014; Kohan, 2006;
Miyauchi, 2004; Vane et al., 1989; Vane et al., 1991, 1993, 1995, 1998;
Webb, 2002).
Coinciding with the 25th anniversary of the discovery of Endothelin
(Emoto and Yanagisawa, 2014), the Thirteenth International Confer-
ence on Endothelin (ET-13) took place in September 2013 on the
Tokyo Campus of the University of Tsukuba in Tokyo, Japan
(Emoto et al., 2014b). The articles published in the proceedings of
ET-13 are compiled in Endothelin XIII, a special issue of the multidis-
ciplinary journal Life Sciences, and include more than 50 articles
spread over [000] pages, which makes it the most comprehensive
endothelin conference proceedings volume of the past decade
(Emoto, 2014).
In celebrating 25 years of the discovery of endothelin, the Endothelin
XIII issue openswith a summary of themeeting, scientistswho delivered
invited lectures and an overview (Emoto and Yanagisawa, 2014),
48 N. Emoto et al. / Life Sciences 118 (2014) 47–50followed by an article describing the history of endothelin research, con-
ference highlights, including all the haikus (Japanese poems) presented
by young investigators, and an outlook on the next generation of
endothelin researchers (Emoto et al., 2014b). The recipient of The Second
Tomoh Masaki Award, Katsutoshi Goto, Ph.D., of Tsukuba University is
honored with an article which summarizes his scientiﬁc achievements
in the ﬁeld of endothelin research (Emoto et al., 2014a). This ﬁrst section
of the journal concludes with an article summarizing the scientiﬁc career
of Wolfgang Kiowski, M.D., who unexpectedly passed away in late 2012
during the planning stages for the ET-13 conference (Barton and
Schiffrin, 2014). Dr. Kiowski had been one of the foremost clinician-
scientists in endothelin research. Twenty years ago, he published a
study reporting the ﬁrst-in-man use of endothelin antagonists in patients
(Kiowski et al., 1995). He had actively participated in many of the past
endothelin conferences, including being amember of their scientiﬁc advi-
sory boards (Barton and Schiffrin, 2014).
The second section of Endothelin XIII comprises a total of nine in-
depth review articles, both from the area of basic sciences as well as
clinical medicine, that have been provided by leaders in their ﬁeld. In
a comprehensive review article, Matthias Barton, M.D., Zurich, who
also celebrated an anniversary that year, discusses the important role
of the endothelin system in aging, and how mechanisms of disease
and the aging process are closely related, and how people can actively
contribute to age healthily (Barton, 2014). Mahalia Desruisseaux, M.D.,
and her colleagues from New York give an extensive review of the liter-
ature highlighting the pathological role of ET-1 in infectious disease
processes and discuss the promising new results suggesting a potential
application of ERAs for infectious disease such as malaria (Freeman
et al., 2014). In his article “EndO' The LineRevisited”, which summarizes
parts of his Honorary Chair Lecture, PaulM. Vanhoutte,M.D. Ph.D., Hong
Kong, discusses the roles of endothelin-1 on vascular tone in the light
50 years of vascular biology research and 25 years of endothelin
research. He also provides his view on the most recent data on the
subject (De Mey and Vanhoutte, 2014). Takayuki Matsumoto, PhD.,
Tokyo, and Rita C. Tostes, Ph.D., Ribeirao Preto, and colleagues provide
an overview on how to link the beneﬁcial effect of current therapies in
diabetes to the endothelin system (Matsumoto et al., 2014). The inter-
play between endothelin and life-threatening ventricular arrhythmias
inmyocardial infarction is discussed by Theoﬁlos Kolettis, M.D. Ioannina
(Kolettis, 2014). Berthold Hocher, M.D., Berlin, contributed a review
articlewhich discusses in detail themany pitfalls that have encountered
the development of endothelin receptor antagonists (ERAs) for patients
with chronic kidney disease and proposes alternatives for the design of
future clinical trials (Reichetzeder et al., 2014). The clinically important
role of endothelin in obesity and diabetes and the therapeutic potential
of endothelin antagonism for related disorders are discussed by
Carmine Cardillo, M.D., Rome, and colleagues (Campia et al., 2014).
Fernando Rodríguez-Pascual, Ph.D. Madrid, and colleagues provide an
extensive overview discussing the controversies about the ambiguous
roles of endothelin in proﬁbrotic diseases and the clinical implications
associated with it (Rodriguez-Pascual et al., 2014), an area also
discussed in the review article about the role of endothelin in aging
(Barton, 2014). Finally, the recipient of the ET-13 Best Presentation
Award for best oral presentation, Johannes Backs, M.D., Heidelberg,
was invited to submit a review article, which gives an excellent and fas-
cinating overview on the role of endothelin-1 in the sympathetic ner-
vous system in the heart (Lehmann et al., 2014b). The data on which
his oral presentation was based (Backs et al., 2013) have been recently
published elsewhere (Lehmann et al., 2014a). The invitation to publish
a review article is part of the award which was introduced in 2012 and
has since been co-sponsored by Elsevier publishers (Barton and Pollock,
2012).
These articles are followed by a large number of high-quality, origi-
nal research articles that reﬂect the complexity of endothelin biologyand at the same time the vitality of this research ﬁeld. In these articles,
data from basic research and clinical studies are presented from the
ﬁelds of nephrology (Certikova Chabova et al., 2013; Heunisch et al.,
2014; Ogura et al., 2014), autoimmunedisease (Tajiri et al., 2014), infec-
tious disease (Naito et al., 2014; Seki et al., 2014), ophthalmology (Finzi
et al., 2014), and cardiac, pulmonary, and vascular research (Backs
et al., 2013; Baretella et al., 2014; Kolettis et al., 2014; Van Hung et al.,
2014), cell biology (Jacobs et al., 2014), physiology (Donato et al.,
2014; Meyer et al., 2014), and oncology (Cianfrocca et al., 2014),
among others. How micro-RNAs might regulate endothelin expression
in different organs and pathological situations is presented by Cain
et al. (Jacobs et al., 2014). The hopes for the treatment of hypertension
raised by novel ERAs are presented by Iglarz et al. (Iglarz et al., 2014),
while Tajiri's results show that an increased inﬂammatory response
might be caused by such an antagonist under certain disease conditions
(Tajiri et al., 2014). Rosano et al. describe themolecular events underly-
ing the potential therapeutic beneﬁt of endothelin antagonism in cancer
(Caprara et al., 2014; Cianfrocca et al., 2014). Many more translational
discoveries were presented in these proceedings that wewere honored
to present as part of Endothelin XIII.
All manuscripts have been rigorously peer-reviewed by at least
three international experts, including members of the Endothelin XIII
Editorial Board. All manuscripts went through at least one to up to
three revisions before they could be accepted. The Guest Editor decided
to continue the format of the proceedings from those introduced with
the preceding conference proceedings, Endothelin XII (Barton, 2012),
particularly with regard to the following points: We are publishing the
ET-13 Conference Proceedings in Life Sciences, a highly respected and
interdisciplinary journal published with Elsevier, who also agreed to
publish all conference abstracts in an online version of the journal
(Emoto, 2013). All conference abstracts and articles of Endothelin XIII
are published Open AccessTM to facilitate the global dissemination and
to allow access for scientists from all over the world (Emoto, 2013).
Video recordings of the conference presentation were available in the
online version for many articles published in Endothelin XII (Barton,
2012; Barton et al., 2012), andwe have continued this tradition publish-
ing articles with corresponding videos, which are freely accessible on
the publisher's website (Emoto, 2014). Also, recordings of most of the
presentations at the conference are available as HD video and can be
accessed via the ET-13 conference program pages of Endothelin XIII
(Conference Program). Finally, as a ﬁrst, each conference abstract has
received a digital object identiﬁer (DOI) and is citable like a regular
article is (Emoto, 2013). We are conﬁdent that this new feature will
facilitate exchange of knowledge in the endothelin ﬁeld and beyond.
We thank all authors for their contributions to this Special Issue of
Life Sciences. We also thank all members of the Life Sciences Endothelin
XIII Special Editorial Board and all of the many reviewers. We thank
them for their enormous efforts put into reviewing the abstracts and
manuscripts submitted, for their tenacity, and for providing insightful
and stimulating comments.We also express our appreciation to Takashi
Miyauchi, M.D. Ph.D., Tsukuba, ET-13 Co-Chair, the entire conference
faculty of ET-13, and the members of Endothelin International Advisory
Board (ET-IAB) of the International Conferences on Endothelin for their
support. We are particularly grateful for the assistance provided by
Nicolas Vignon-Zellweger, Ph.D. for his energy and his administrative
talent. We are indebted to Anne Marie Pordon, Ph.D. of Elsevier as the
publisher of Life Sciences for her professional support. We thank Loren
Wold, Ph.D., Columbus, OH, Editor-in-Chief of Life Sciences, for his trust
in this project, and Christine Kisthardt and Ruthie Hewitt at Life Sciences,
for their sensational support through the whole process of publishing
the proceedings. We also wish to thank all participants, sponsors, and
the musicians Dimitri and Vovka Ashkenazy for their concert perfor-
mance on occasion of the 25th anniversary of the discovery of endothelin
in Tokyo.
49N. Emoto et al. / Life Sciences 118 (2014) 47–50We hope that you will enjoy this ET-13 Special Issue of Life Sciences
and look forward to meeting you again in 2015 at ET-14 which will be
held in Savannah, Georgia.
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Supplementary video to this article “Highlights of ET-13 - Professor
Masashi Yanagisawa’s summary of the conference” can be found online
at http://dx.doi.org/10.1016/j.lfs.2014.09.021.References
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